Status:
WITHDRAWN
Rifaximin Versus Lactulose in Renal Failure
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Liver Cirrhosis
Renal Failure
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less freque...
Eligibility Criteria
Inclusion
- cirrhosis of liver of any etiology
- progressive renal failure
- stage 0-2 hepatic encephalopathy
Exclusion
- pregnant women
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00748904
Start Date
June 1 2008
End Date
July 1 2009
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical Center
New York, New York, United States, 10021